Watanabe Akihiro, Kodera Masanari, Sugiura Kazumitsu, Usuda Toshikazu, Tan Eng M, Takasaki Yoshinari, Tomita Yasushi, Muro Yoshinao
Nagoya University Graduate School of Medicine, Nagoya, Japan.
Arthritis Rheum. 2004 Mar;50(3):892-900. doi: 10.1002/art.20096.
Autoantibodies against DFS70 (dense fine speckles 70) antigen (also known as lens epithelium-derived growth factor) have been recently identified among the antinuclear antibodies (ANAs) in patients with atopic disorders. We undertook this study to examine the frequency of anti-DFS70 antibodies in a large number of healthy people.
Sera of 597 healthy individuals working in a hospital (142 men, 455 women) were analyzed for ANAs and for anti-DFS70 antibodies by indirect immunofluorescence (IIF) with HEp-2 cells as a substrate and by immunoblotting using DFS70 recombinant protein and whole HeLa cell extract.
ANAs were present in 20% of all individuals by IIF. Nine percent of subjects were ANA positive at a serum dilution of 1:40, 4.0% at 1:80, 5.5% at 1:160, 1.0% at 1:320, and 0.3% at 1:640. There were 64 anti-DFS70 antibody-positive individuals. Surprisingly, this was 11% of the whole population and 54% of the ANA-positive population. The percentage of female anti-DFS70 antibody-positive subjects (86%; 55 of 64 subjects) was higher than the percentage of female anti-DFS70 antibody-negative subjects (75%; 398 of 533 subjects) (P < 0.05). The prevalence of anti-DFS70 antibody-positive sera decreased with increasing age (P = 0.0017).
Considering that anti-DFS70 antibody positivity is rare in patients with systemic autoimmune diseases, introducing the anti-DFS70 antibody examination as a screening test for ANA-positive persons could be used to rule out systemic autoimmune diseases, resulting in considerable cost-saving potential. In addition, this test defines a subpopulation of healthy people in whom long-term followup might reveal health-related implications of this finding, since anti-DFS70 antibodies have been shown to be associated with some illnesses.
近期在特应性疾病患者的抗核抗体(ANA)中发现了针对DFS70(致密细斑点70)抗原(也称为晶状体上皮衍生生长因子)的自身抗体。我们开展这项研究以检测大量健康人群中抗DFS70抗体的频率。
采用以HEp-2细胞为底物的间接免疫荧光法(IIF)以及使用DFS70重组蛋白和完整HeLa细胞提取物的免疫印迹法,对一家医院的597名健康个体(142名男性,455名女性)的血清进行ANA和抗DFS70抗体检测。
通过IIF检测,所有个体中有20%存在ANA。在血清稀释度为1:40时,9.0%的受试者ANA呈阳性,1:80时为4.0%,1:160时为5.5%,1:320时为1.0%,1:640时为0.3%。有64名个体抗DFS70抗体呈阳性。令人惊讶的是,这占整个人口的11%,占ANA阳性人群的54%。抗DFS70抗体呈阳性的女性受试者百分比(86%;64名受试者中的55名)高于抗DFS70抗体呈阴性的女性受试者百分比(75%;533名受试者中的398名)(P<0.05)。抗DFS70抗体阳性血清的患病率随年龄增长而降低(P = 0.0017)。
鉴于抗DFS70抗体阳性在系统性自身免疫性疾病患者中罕见,将抗DFS70抗体检测作为ANA阳性者的筛查试验可用于排除系统性自身免疫性疾病,具有可观的成本节约潜力。此外,该检测确定了一部分健康人群,对其进行长期随访可能会揭示这一发现与健康相关的影响,因为抗DFS70抗体已被证明与某些疾病有关。